| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | EAC; MFT; SBS; TEM; BRSS; CDMT; MFT1; CYLD1; CYLDI; USPL2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CYLD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与CYLD抗体相关的代表性文献，简要概括研究内容：
1. **《The tumor suppressor CYLD regulates entry into mitosis》**
- 作者：Masoumi, K.C., et al.
- 摘要：研究揭示CYLD通过去泛素化Aurora B激酶调控细胞周期进程，CYLD抗体被用于检测其在有丝分裂中的定位及表达水平变化。
2. **《CYLD inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling》**
- 作者：Massoumi, R., et al.
- 摘要：发现CYLD通过抑制NF-κB通路关键因子Bcl-3的活性发挥抑癌作用，研究中使用CYLD抗体验证其在多种癌细胞系中的蛋白表达缺失。
3. **《Loss of the cylindromatosis tumor suppressor inhibits apoptosis by activating NF-κB》**
- 作者：Brummelkamp, T.R., et al.
- 摘要：证实CYLD缺失导致NF-κB信号异常激活并抑制细胞凋亡，通过CYLD抗体染色显示其在正常组织与肿瘤样本中的表达差异。
4. **《Antibody-based detection of CYLD in human tissues: implications for skin cancer diagnostics》**
- 作者：Tauriello, D.V.F., et al.
- 摘要：开发特异性CYLD抗体用于皮肤肿瘤诊断，证明CYLD表达缺失与圆柱瘤等皮肤附件肿瘤的发生密切相关。
注：以上文献为领域内经典研究示例，实际引用时请核对最新文献及具体实验背景需求。
The CYLD antibody is a crucial tool in studying the CYLD gene, which encodes a deubiquitinating enzyme regulating key signaling pathways like NF-κB and JNK. Initially identified as a tumor suppressor linked to familial cylindromatosis, CYLD mutations are associated with skin appendage tumors and other cancers. The CYLD protein modulates inflammatory responses, cell proliferation, and apoptosis by removing ubiquitin chains from substrates such as TRAF2. TRAF6. and BCL-3. Dysregulation of CYLD disrupts these pathways, promoting oncogenesis.
CYLD antibodies are widely used in research to detect CYLD expression levels, localization, and post-translational modifications via techniques like Western blot, immunohistochemistry, and immunofluorescence. They also help identify CYLD-interacting proteins through co-immunoprecipitation. Commercially available CYLD antibodies vary in specificity, targeting distinct epitopes (e.g., N-terminal, C-terminal, or full-length protein). Validation across applications is critical due to potential cross-reactivity.
Research using CYLD antibodies has clarified its role in tumor suppression, immune regulation, and response to therapies. Dysfunctional CYLD is implicated in melanoma, colon cancer, and multiple myeloma, making it a potential therapeutic target. These antibodies remain essential for exploring CYLD’s molecular mechanisms and translational relevance in disease.
×
